Holen Sie sich die Stockscreener-App
53.78
3.29%
-1.83
Handel nachbörslich:
53.78
Astrana Health Inc Aktie (ASTH) Neueste Nachrichten
Do You Believe in the Long-Term Growth Potential of Astrana Health (ASTH)? - Yahoo Finance
Analysts Estimate Astrana Health, Inc. (ASTH) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Astrana Health (ASTH) to Release Quarterly Earnings on Thursday - MarketBeat
SteelPeak Wealth LLC Acquires Shares of 679,984 Astrana Health, Inc. (NASDAQ:ASTH) - MarketBeat
Short Interest in Astrana Health, Inc. (NASDAQ:ASTH) Declines By 16.2% - MarketBeat
Astrana Health, Inc. (NASDAQ:ASTH) Receives Average Rating of "Buy" from Brokerages - MarketBeat
NorthCrest Asset Manangement LLC Purchases New Holdings in Astrana Health, Inc. (NASDAQ:ASTH) - MarketBeat
Guidance Capital Inc. Purchases New Stake in Astrana Health, Inc. (NASDAQ:ASTH) - MarketBeat
Astrana Health, Inc. Schedules 2024 Third Quarter Financial Results Release and Conference Call - WV News
Astrana Health (NASDAQ:ASTH) jumps 9.7% this week, though earnings growth is still tracking behind five-year shareholder returns - Simply Wall St
Astrana Health (NASDAQ:ASTH) Reaches New 12-Month HighHere's What Happened - MarketBeat
Astrana Health (NASDAQ:ASTH) Sees Strong Trading VolumeHere's Why - MarketBeat
Astrana Health gets Buy rating from TD Cowen amid expansion progress - Investing.com Australia
Astrana Health (NASDAQ:ASTH) Now Covered by TD Cowen - MarketBeat
SG Americas Securities LLC Purchases Shares of 11,742 Astrana Health, Inc. (NASDAQ:ASTH) - MarketBeat
KeyBanc starts Astrana Health coverage with Sector Weight rating By Investing.com - Investing.com Canada
Astrana Health (NASDAQ:ASTH) Receives New Coverage from Analysts at KeyCorp - MarketBeat
KeyBanc starts Astrana Health coverage with Sector Weight rating - Investing.com
Astrana Health to buy Collaborative Health Systems - MSN
Centene completes sale of management services subsidiary - Healthcare Dive
Astrana Health acquires CHS to expand care delivery capabilities - Yahoo! Voices
Astrana Health completes acquisition of healthcare networks By Investing.com - Investing.com Australia
Astrana Health completes acquisition of healthcare networks - Investing.com
Healthy Upside Potential: Astrana Health Inc. (ASTH) - SETE News
Astrana Health Completes Acquisition of Collaborative Health Systems - PR Newswire
Astrana Health, Inc.'s (NASDAQ:ASTH) P/E Is Still On The Mark Following 25% Share Price Bounce - Simply Wall St
Astrana Health shares poised for growth with updated price target amid competitive landscape By Investing.com - Investing.com South Africa
Astrana Health shares poised for growth with updated price target amid competitive landscape - Investing.com
Astrana Health (NASDAQ:ASTH) Sets New 52-Week High Following Analyst Upgrade - Defense World
Astrana Health, Inc. (NASDAQ:ASTH) Given Average Recommendation of "Buy" by Analysts - MarketBeat
BTIG Research Increases Astrana Health (NASDAQ:ASTH) Price Target to $70.00 - MarketBeat
What 5 Analyst Ratings Have To Say About Astrana Health - Benzinga
500: Something went wrong - Investing.com UK
SCAN, Astrana Launch MA Plan Tailored to Asian Older Adults - MedCity News
Be Wary Of Astrana Health (NASDAQ:ASTH) And Its Returns On Capital - Yahoo Finance
Ascential Shareholding Shifts with Societe Generale’s Move - TipRanks
Magnetar Financial LLC Buys Shares of 20,305 Astera Labs, Inc. (NASDAQ:ALAB) - Defense World
Views of Wall Street’s Leading Experts on Astera Labs Inc. - SETE News
Prospects for datopotamab deruxtecan dented by update - The Pharma Letter
AstraZeneca shares rally 13%, hit record high as firm gets nod for cancer drug Durvalumab - CNBCTV18
Astera Labs, Inc. (NASDAQ:ALAB) Shares Sold by American Century Companies Inc. - Defense World
AstraZeneca Pharma gets nod to sell immunotherapy drug Durvalumab; stock surges - Fortune India
AstraZeneca Pharma shares rally 13%, hit 52-week high after receiving nod for cancer drug Durvalumab - The Economic Times
AstraZeneca Pharma Shares Surge 12% After Approval to Launch Cancer Drug in India - EquityPandit
Pharma stock jumps 12% after it receives nod to import drugs for cancer and tumors - Trade Brains
AstraZeneca Pharma receives nod for cancer drug Durvalumab; stock soars 12% - Business Standard
AstraZeneca stock surges over 8% – Check out the reason behind it - Business Upturn
AstraZeneca Pharma India gains on import nod for cancer drug - XM
Astec Lifesciences: Brokerage revises stock's rating post CEO exitDetails - ET Now
AstraZeneca Pharma shares jump 12% to 52-week high on CDSCO permission - Moneycontrol
Aclarion shareholders approve reverse stock split proposal By Investing.com - Investing.com Australia
AstraZeneca Stock Dips On Surprise Miss For Gilead-Rivaling Cancer Drug - Investor's Business Daily
This Is What Whales Are Betting On Astera Labs - Benzinga
Indian giant swoops to take over Scottish company - HeraldScotland
Will Astera Labs Inc. (ALAB) meet earnings estimates this quarter? - US Post News
AstraZeneca falls Monday, underperforms market - MarketWatch
Poor trial results dash AstraZeneca’s hopes for $1bn cancer drug - The Times
ProShare Advisors LLC Sells 79,195 Shares of AstraZeneca PLC (NASDAQ:AZN) - Defense World
2.34%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):